News articles about Perrigo (NYSE:PRGO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Perrigo earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.1762565281807 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Nicotine Gum Market Global Forecast 2018-2022- Fertin Pharma, Novartis, Pfizer and Perrigo Company (businessservices24.com)
- Podophyllin Market Global Forecast 2018-2022- Haoxiang, Himpharm, MP Biomedicals and Perrigo (businessservices24.com)
- Mrs. Lila M. Thompson, 84, of Massena (wwnytv.com)
- Perrigo (PRGO) Research Coverage Started at Berenberg Bank (americanbankingnews.com)
- Perrigo’s (PRGO) Buy Rating Reiterated at Oppenheimer (americanbankingnews.com)
Several equities research analysts have recently weighed in on PRGO shares. Barclays increased their target price on shares of Perrigo to $93.00 and gave the company an “overweight” rating in a research note on Monday, December 4th. Canaccord Genuity reissued a “buy” rating and issued a $100.00 target price on shares of Perrigo in a research note on Wednesday, January 17th. Leerink Swann started coverage on shares of Perrigo in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $90.00 target price on the stock. Oppenheimer set a $98.00 target price on shares of Perrigo and gave the company a “buy” rating in a research note on Monday, March 5th. Finally, Cantor Fitzgerald set a $107.00 target price on shares of Perrigo and gave the company a “buy” rating in a research note on Friday, January 19th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the stock. Perrigo presently has an average rating of “Hold” and an average price target of $91.88.
Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, March 1st. The company reported $1.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.03. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.26 billion. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The firm’s revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.24 EPS. analysts predict that Perrigo will post 5.23 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 20th. Investors of record on Friday, March 2nd were paid a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend was Thursday, March 1st. This is an increase from Perrigo’s previous quarterly dividend of $0.16. Perrigo’s dividend payout ratio (DPR) is currently 90.48%.
In other Perrigo news, VP Todd W. Kingma sold 1,500 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the transaction, the vice president now directly owns 19,565 shares in the company, valued at approximately $1,731,893.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Uwe Roehrhoff bought 7,500 shares of the company’s stock in a transaction on Monday, March 5th. The shares were acquired at an average price of $81.85 per share, for a total transaction of $613,875.00. Following the completion of the acquisition, the chief executive officer now owns 4,900 shares in the company, valued at $401,065. The disclosure for this purchase can be found here. Company insiders own 6.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3303225/perrigo-prgo-earning-somewhat-favorable-news-coverage-analysis-shows.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.